FDG-PET in the Diagnosis of Autoimmune Encephalitis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06019975

Acronym

PEA

Enrollment

Registered

2023-08-31

Start date

2023-03-01

Completion date

2027-04-30

Last updated

2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Encephalitis

Keywords

Autoimmune Encephalitis, FDG-PET, SPM

Brief summary

The goal of this retrospective observational study is to compare brain fluorodeoxyglucose-positron emission tomography (FDG-PET) of patients with autoimmune encephalitis, normal controls and patients with Alzheimer's disease (AD). The main question it aims to answer is: •is there a specific pattern of brain metabolism in patients with autoimmune encephalitis Participants data and images will be retrospectively collected from hospital records, and FDG-PET images will be analyzed by means of statistical parametric mapping (SPM). Controls will be selected from validated public databases.

Interventions

DIAGNOSTIC_TESTFDG-PET

Brain FDG-PET

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Diagnosis of autoimmune encephalitis according to clinical criteria * Brain magnetic resonance imaging performed between clinical presentation and treatment * Cerebrospinal fluid analysis performed between clinical presentation and treatment * Brain FDG-PET performed between clinical presentation and treatment * Autoantibodies testing performed between clinical presentation and treatment

Exclusion criteria

* Refusal to give consent for the study

Design outcomes

Primary

Measure	Time frame	Description
SPM analysis of brain metabolic pattern	up to 6 months	Pattern of brain metabolism in patients with autoimmune encephalitis compared with healthy controls and patients with Alzheimer's disease, drawn from validated published databases

Secondary

Measure	Time frame	Description
Sensitivity of basal ganglia hypermetabolism	up to 6 months	Sensitivity of basal ganglia hypermetabolism for the diagnosis of autoimmune encephalitis
Diagnostic delay	up to 6 months	Comparison of diagnostic delay with and without FDG-PET

Countries

Italy

Contacts

CONTACTSimone Beretta, MD, PhD

simone.beretta@unimib.it+390392333568

CONTACTFederico Emanuele Pozzi, MD

federicoemanuele.pozzi@gmail.com

PRINCIPAL_INVESTIGATORSimone Beretta, MD, PhD

University of Milano Bicocca

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026